VENUS REMEDIES
Quarterly Results Analysis [Dec2023]
VENUS REMEDIES Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹143 Cr | ₹168 Cr | ₹95 Cr | ₹156 Cr | ₹117 Cr | ₹140 Cr | ₹143 Cr | ₹142 Cr |
Expenses | ₹131 Cr | ₹150 Cr | ₹85 Cr | ₹131 Cr | ₹109 Cr | ₹127 Cr | ₹129 Cr | ₹137 Cr |
Operating Income | ₹12 Cr | ₹18 Cr | ₹10 Cr | ₹25 Cr | ₹8 Cr | ₹13 Cr | ₹15 Cr | ₹6 Cr |
Other Income | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹7 Cr | ₹6 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr |
Profit Before Tax | ₹8 Cr | ₹14 Cr | ₹5 Cr | ₹20 Cr | ₹5 Cr | ₹6 Cr | ₹8 Cr | ₹0 Cr |
Profit After Tax | ₹7 Cr | ₹10 Cr | ₹1 Cr | ₹11 Cr | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹0 Cr |
EPS | ₹5.12 | ₹7.43 | ₹0.88 | ₹8.27 | ₹2.46 | ₹3.99 | ₹5.15 | ₹0.17 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | -4% | -12.1% | 89.2% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
VENUS REMEDIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -14.49 % |
Y-o-Y | 22.69 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹143 Cr | -14.49 | |
Sep2023 | ₹168 Cr | 76.27 | |
Jun2023 | ₹95 Cr | -38.87 | |
Mar2023 | ₹156 Cr | 33.14 | |
Dec2022 | ₹117 Cr | -16.43 | |
Sep2022 | ₹140 Cr | -2.23 | |
Jun2022 | ₹143 Cr | 0.44 | |
Mar2022 | ₹142 Cr | - |
VENUS REMEDIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -32.32 % |
Y-o-Y | 48.64 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹12 Cr | -32.32 | |
Sep2023 | ₹18 Cr | 71.06 | |
Jun2023 | ₹10 Cr | -57.74 | |
Mar2023 | ₹25 Cr | 203.83 | |
Dec2022 | ₹8 Cr | -37.55 | |
Sep2022 | ₹13 Cr | -10.61 | |
Jun2022 | ₹15 Cr | 161.91 | |
Mar2022 | ₹6 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -20.92 % |
Y-o-Y | 21.07 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 8.39% | -20.92 | |
Sep2023 | 10.61% | -2.93 | |
Jun2023 | 10.93% | -30.87 | |
Mar2023 | 15.81% | 128.14 | |
Dec2022 | 6.93% | -25.24 | |
Sep2022 | 9.27% | -8.58 | |
Jun2022 | 10.14% | 160.67 | |
Mar2022 | 3.89% | - |
VENUS REMEDIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -31.09 % |
Y-o-Y | 108.21 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹7 Cr | -31.09 | |
Sep2023 | ₹10 Cr | 742.37 | |
Jun2023 | ₹1 Cr | -89.33 | |
Mar2023 | ₹11 Cr | 236.17 | |
Dec2022 | ₹3 Cr | -38.27 | |
Sep2022 | ₹5 Cr | -22.64 | |
Jun2022 | ₹7 Cr | 2,895.65 | |
Mar2022 | ₹0 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -19.39 % |
Y-o-Y | 70.11 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 4.78 % | -19.39 | |
Sep2023 | 5.93 % | 378.23 | |
Jun2023 | 1.24 % | -82.56 | |
Mar2023 | 7.11 % | 153.02 | |
Dec2022 | 2.81 % | -26.25 | |
Sep2022 | 3.81 % | -20.95 | |
Jun2022 | 4.82 % | 2,912.50 | |
Mar2022 | 0.16 % | - |
VENUS REMEDIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -31.09 % |
Y-o-Y | 108.13 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹5.12 | -31.09 | |
Sep2023 | ₹7.43 | 744.32 | |
Jun2023 | ₹0.88 | -89.36 | |
Mar2023 | ₹8.27 | 236.18 | |
Dec2022 | ₹2.46 | -38.35 | |
Sep2022 | ₹3.99 | -22.52 | |
Jun2022 | ₹5.15 | 2,929.41 | |
Mar2022 | ₹0.17 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD